Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis

Abstract Introduction Ofatumumab demonstrated superior efficacy and similar safety versus teriflunomide in ASCLEPIOS I/II in people with relapsing multiple sclerosis; no new safety concerns and sustained efficacy were observed up to 4 years in the open-label extension study ALITHIOS. Here, we furthe...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Stephen L. Hauser, Jeffrey A. Cohen, Jérôme de Sèze, Sven G. Meuth, Paul S. Giacomini, Jin Nakahara, Celia Oreja-Guevara, Derrick Robertson, Sibyl Wray, Alit Bhatt, Xixi Hu, Jing Xi, Rebecca Piccolo, Valentine Jehl, Roseanne Sullivan, Ibolya Boer, Heinz Wiendl, Ludwig Kappos
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2025-07-01
coleção:	Neurology and Therapy
Assuntos:	Disability High-efficacy therapies Ofatumumab Relapsing multiple sclerosis Safety
Acesso em linha:	https://doi.org/10.1007/s40120-025-00784-0
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!